Calendario›SNY›A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in Taiwan
Ensayo de Sanofi en Dermatitis atopica.
Más ensayos de: Dermatitis atópica.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 80
- Centros
- 1
- Fin del objetivo primario
- jun 2023
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en jul 2022.
Qué mide
Characterization of the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment: Used regimens (At baseline (Day 1)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroPrimary objective: To characterize the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment for adult AD patients, who are eligible for dupilumab reimbursement in Taiwan (e.g., used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching). Secondary objectives: * To characterize the adult AD patients, who are eligible for dupilumab reimbursement in Taiwan, with respect to their a) medical history, b) socio-demographic, c) disease characteristics, d) comorbid with type 2 diseases \[e.g., Asthma, Chronic rhinosinusitis with nasal polyp (CRSwNP)\], and e) prior and concomitant treatments of atopic dermatitis * To assess the effectiveness and safety of dupilumab in adult atopic dermatitis patients, who are eligible for dupilumab reimbursement in Taiwan * To assess comorbid atopic conditions and effects of dupilumab treatment for comorbid atopic conditions in adult patients, who are eligible for dupilumab reimbursement in Taiwan * To evaluate the correlation of patient reported outcome \[Atopic Dermatitis Control Tool (ADCT)\] and physician assessment \[Eczema Area and Severity Index (EASI)\] from the recruited subjects
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05442645), actualizada en jul 2024.